Torrent Pharmaceuticals received a U.S. Patent for novel heterocyclic compounds

Ahmedabad-based Torrent Pharmaceuticals Ltd. has recently received a U.S. Patent No. 7,138,416 (the ‘416 patent) directed to a novel heterocyclic compounds of general formula I and its pharmaceutically acceptable salts useful for (i) normalizing elevated blood glucose levels in diabetics, (ii) treating disorders related to glucose intolerance and (iii) scavenging free radicals from body cells. The ‘416 patent explicitly discloses list of 115 representative compounds covered within the structural scope of general formula I. According to the ‘416 patent disclosure, compounds of general formula I exhibit in vitro dipeptidyl peptidase-IV (DPP-IV) inhibitory activity.